BAY 57-1293
Item No. 22129

CAS Registry No.: 348086-71-5
Formal Name: N-[5-(amino sulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-py ri diny l)-benzenac etamide
MF: C18H18N4O3S2
FW: 402.5
Purity: ≥ 98%
UV/Vis.: λmax.: 247, 283 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥ 2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAY 57-1293 is supplied as a crystalline solid. A stock solution may be made by dissolving the BAY 57-1293 in the solvent of choice. BAY 57-1293 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of BAY 57-1293 in these solvents is approximately 30 mg/ml.

Description

BAY-57-1293 is an orally bioavailable helicase-primase inhibitor.\textsuperscript{1} It inhibits the ATPase activity of herpes simplex virus (HSV) helicase-primase (IC\textsubscript{50} = 30 nM). It inhibits HSV replication in Vero cells (IC\textsubscript{50} = 20 nM for both HSV-1 and HSV-2) and is also active against porcine and bovine HSV strains (IC\textsubscript{50}s = 5 and 0.12 μM, respectively). In vivo, oral administration of BAY-57-1293 is effective against HSV-1 and HSV-2 in a lethal challenge model (ED\textsubscript{50} = 0.5 mg/kg) and in a zosteriform spread model, at a dose of 15 mg/kg, in mice and Lewis rats.\textsuperscript{1,2} It is also effective in a guinea pig model of genital herpes and a mouse model of ocular herpes. BAY-57-1293 reduces levels of amyloid β (Aβ) and phosphorylated Tau in HSV-1 infected Vero cells.\textsuperscript{3}

References